Merus MRUS 深 滬
等待開盤 12-13 09:30:00 美东时间
96.90
+0.270
+0.28%
華盛通- 最 高96.93
- 今 開96.80
- 成交量 22.57万股
- 最 低 96.80
- 昨 收 96.63
- 總市值 73.44亿
- 52周最高 96.93
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 33.19
- 委 比 -51.93%
- 總股本 7578.44万
- 歷史最高 96.93
- 量 比 0.69
- 振 幅 0.13%
- 歷史最低 7.255
- 每 手 1
- 風險率 20.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Merus Acquired by Genmab, Leadership Changes Announced
An announcement from Merus ( ($MRUS) ) is now available. On December 11, 2025, ...
12-12 21:18
Jim Lang Elected to Halozyme's Board of Directors
SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than ...
12-09 05:05
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction orderi...
12-05 02:26
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer
Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.
11-19 01:58
Merus N.V. Shareholders to Vote on Genmab Acquisition Offer
New activity is brewing for Merus ( ($MRUS) ). The company has submitted a Form...
11-12 21:40
Genmab To Offer $1.5B Of Senior Secured Notes Due 2032 And $1B Of Senior Unsecured Notes Due 2033, The Company Also Launched The Syndication Of A New $2B Senior Secured Term Loan In Addition To A $1B Senior Secured Term Loan Facility And $500M Senior Secured Revolving Credit Facility To Finance The Merus Acquisition
https://ml-eu.globenewswire.com/Resource/Download/446c3266-6d5c-48ac-9a4e-4d559364ceb1
11-10 20:25
Merus Announces Interim Clinical Data From Ongoing Phase 2 Trial Of Bispecific Antibody Petosemtamab In Metastatic Colorectal Cancer In Combination With FOLFOX/FOLFIRI
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed)– 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct.
10-24 22:04
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Merus N.V. announced interim results from a phase 2 trial of petosemtamab in metastatic colorectal cancer (mCRC). In 1L left-sided mCRC, 100% response rate was observed (n=8). In 2L mCRC, a 62% response rate was noted (n=13). Petosemtamab showed promising efficacy and a consistent safety profile across treatment lines, with no new safety signals identified. These findings highlight its potential as a transformative treatment for mCRC patients.
10-24 14:00
Why Is Genmab Stock Trading Lower On Monday?
Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities.
10-20 23:57
Merus Reveals Petosemtamab In Metastatic Colorectal Cancer Abstract Selected For Plenary Session Oral Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics, Being Held In Boston, Massachusetts On October 22-26, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific
10-14 00:04
